OncoMatch/Clinical Trials/NCT07277413
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Is NCT07277413 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including IDE892 and IDE397 for nsclc adenocarcinoma.
Treatment: IDE892 · IDE397 — This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Gastric Cancer
Esophageal Carcinoma
Urothelial Carcinoma
Mesothelioma
Pancreatic Cancer
Biomarker criteria
Required: MTAP deletion
evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced or metastatic disease
Must have progressed following at least 1 prior line of therapy; treatment with no more than 3 prior lines in the setting of advanced or metastatic disease
Cannot have received: Amethionine adenosyltransferase 2A (MAT2A) inhibitor
Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor
Cannot have received: Protein arginine N-methyltransferase (PRMT) inhibitor
Previous treatment with a ... Protein arginine N-methyltransferase (PRMT) inhibitor
Cannot have received: irradiation to > 25% of the bone marrow
Prior irradiation to > 25% of the bone marrow
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Have adequate bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Providence Medical Foundation · Santa Rosa, California
- Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, Florida
- Nebraska Cancer Specialists · Omaha, Nebraska
- START Astera, LLC · East Brunswick, New Jersey
- Columbia University Irving Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07277413 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Amethionine adenosyltransferase 2A (MAT2A) inhibitor, Protein arginine N-methyltransferase (PRMT) inhibitor, irradiation to > 25% of the bone marrow disqualifies patients from enrollment.
Does this trial require MTAP?
Yes, MTAP deletion is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify